Return to Physical Activity After Retropublic Transvaginal Sling and Laparoscopic Sacrocolpopexy (RETURN)
Return to Physical Activity and Early Recovery After Urogynaecological Surgery: a Prospective Observational Two-Cohort Study
Advice on how long to limit physical activity after pelvic floor surgery ranges from 2 to 12 weeks and rests mainly on local tradition rather than data. This prospective observational study follows women undergoing a retropubic midurethral sling (TVT) for stress urinary incontinence or a laparoscopic sacrocolpopexy for pelvic organ prolapse at a single centre in Poland. For 6 weeks after surgery, participants keep a weekly diary of ten everyday activities, pain, and the reasons for not resuming each activity, and they complete validated questionnaires up to 6 months. The study does not change any aspect of treatment. Its main aim is to estimate the time to return to the pre-operative level of physical activity in each cohort.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Background. Recommended periods of activity restriction after urogynaecological surgery vary between 2 and 12 weeks for the same procedure. Most existing data come from secondary analyses of trials or from retrospective questions asked months after surgery, which are prone to recall bias. In a secondary analysis of the TOMUS trial, fewer than half of women resumed normal activities within 2 weeks of a midurethral sling, and timing of return was not associated with treatment failure or adverse events. Randomised trials after midurethral sling and prolapse surgery found that shorter or liberal restrictions did not compromise outcomes and improved satisfaction. Prospective, real-time data on when women resume specific activities, what stops them, and how this differs between procedures are lacking, as are data from Central and Eastern Europe.
Objectives. Primary: to estimate the time to return to the pre-operative level of physical activity after retropubic midurethral sling and after laparoscopic sacrocolpopexy. Secondary: (1) to describe return to ten predefined everyday activities during the first 6 postoperative weeks; (2) to assess whether pain intensity in the first postoperative week predicts the pace of return; (3) to identify reasons for not resuming activity, distinguishing adherence to medical advice from fear of harming the surgical result; (4) to identify clinical factors associated with slower return; (5) to assess the quality of early recovery and satisfaction with treatment.
Design. Prospective, non-interventional, single-centre study with two parallel cohorts and follow-up to 6 months. Surgical indication, technique and postoperative advice follow routine practice and are not influenced by the study. Postoperative instructions are standardised within each cohort. Reporting will follow STROBE.
Data collection. The investigator completes a case report form from the medical record and routine examination (demographics, obstetric and surgical history, POP-Q, modified Oxford scale, intra-operative data, Clavien-Dindo complications, 30-day urinary tract infection and readmission). Participants complete questionnaires at scheduled routine visits and keep a home diary identified only by a study number. The diary contains a weekly activity card (ten activities: walking ≥30 min, light housework, yoga/Pilates/stretching, cycling, strenuous exercise, driving, paid work, lifting >5 kg, swimming, sexual intercourse; the last three from week 4), a pain card (NRS 0-10 daily on days 0-7, then weekly) and a card recording the date each activity was first performed.
Schedule.
At baseline, both cohorts complete IPAQ-SF, the Tegner activity scale and PFDI-20, and undergo POP-Q, ICIQ-UI SF and modified Oxford assessment. On postoperative day 1, both cohorts complete QoR-15. During weeks 1-6, participants keep the diary and complete IPAQ-SF weekly. At 6 weeks, both cohorts complete IPAQ-SF, Tegner, PFDI-20 and ICIQ-S; cohort A also completes ICIQ-UI SF, and cohort B undergoes POP-Q. At 3 months, cohort B completes IPAQ-SF and, if not fully returned to activity by week 6, the date card. At 6 months, the 6-week assessments are repeated in both cohorts.
Statistical analysis (proposed). Time to return will be analysed with Kaplan-Meier estimates per cohort, censoring participants who have not returned by the end of diary follow-up. The association of mean week-1 pain and clinical factors with time to return will be assessed with Cox proportional hazards models. Reasons for non-resumption will be summarised as proportions per activity and week. Questionnaire scores will be compared with baseline using mixed-effects models for repeated measures. The two cohorts are analysed descriptively side by side; they differ in indication and procedure and are not intended for causal comparison.
Ethics and data protection. Written informed consent is obtained before enrolment and may be withdrawn at any time without consequences for care. Data are pseudonymised at collection; the key linking study numbers to identities is held separately by the principal investigator. Results will be published in aggregate form only.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Luoghi di studio
-
-
-
Wroclaw, Polonia, 50-233
- Department of Minimally Invasive Gynaecology with Pelvic Floor Disorders Centre, Public Healthcare Centre of the Ministry of Interior and Administration
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Consecutive adult women scheduled for retropubic midurethral sling or laparoscopic sacrocolpopexy at the Department of Minimally Invasive Gynaecology, Public Healthcare Centre of the Ministry of Interior and Administration, Wrocław, Poland.
Descrizione
Inclusion Criteria:
- Women aged 18 years or older
- Scheduled for isolated retropubic midurethral sling (cohort A) or laparoscopic sacrocolpopexy with or without hysterectomy (cohort B)
- Written informed consent
- Able to complete questionnaires and keep the diary independently
Exclusion Criteria:
- Pregnancy
- Active malignancy under oncological treatment
- Significant cognitive impairment preventing questionnaire completion
- Neurological or orthopaedic conditions preventing independent walking before surgery
- Cohort A only: concomitant pelvic floor or gynaecological procedure
- Refusal or withdrawal of consent
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: OTHER
- Prospettive temporali: PROSPECTIVE
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Cohort A: Retropubic midurethral sling
Women undergoing isolated retropubic midurethral sling (TVT) for stress or stress-predominant mixed urinary incontinence, without concomitant procedures. |
Surgical procedure performed as part of routine clinical care according to standard indications. The study does not influence the decision to operate, the surgical technique or postoperative advice. Patient-reported questionnaires - Validated Polish versions of IPAQ-SF, the Tegner activity scale, PFDI-20, QoR-15, ICIQ-S, ICIQ-UI SF. Completed at baseline, postoperative day 1, weekly to 6 weeks (IPAQ-SF), 6 weeks, 3 months (cohort B) and 6 months. |
|
Cohort B: Laparoscopic sacrocolpopexy
Women undergoing laparoscopic sacrocolpopexy for pelvic organ prolapse, with or without concomitant supracervical or total hysterectomy; other concomitant procedures are permitted and recorded. |
Surgical procedure performed as part of routine clinical care according to standard indications. The study does not influence the decision to operate, the surgical technique or postoperative advice. Patient-reported questionnaires - Validated Polish versions of IPAQ-SF, the Tegner activity scale, PFDI-20, QoR-15, ICIQ-S, ICIQ-UI SF. Completed at baseline, postoperative day 1, weekly to 6 weeks (IPAQ-SF), 6 weeks, 3 months (cohort B) and 6 months. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Time to return to the pre-operative level of physical activity
Lasso di tempo: From surgery to 6 months
|
Days from surgery to the end of the first diary week in which the participant reports full return ("yes") to her usual pre-operative activity level. |
From surgery to 6 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Time to first performance of each predefined activity
Lasso di tempo: From surgery to 6 months.
|
Days from surgery to the first performance of each of ten everyday activities, recorded on the diary date card. |
From surgery to 6 months.
|
|
Early postoperative pain as a predictor of return to activity
Lasso di tempo: From surgery to 6 months.
|
Association between mean pain intensity (NRS 0-10) on postoperative days 0-7 and time to return to the pre-operative activity level (hazard ratio). |
From surgery to 6 months.
|
|
Reasons for not performing activities.
Lasso di tempo: Weeks 1-6
|
Proportion of coded reasons per activity and week, distinguishing adherence to medical advice from fear of harming the surgical result. |
Weeks 1-6
|
|
Clinical factors associated with slower return to activity.
Lasso di tempo: From surgery to 6 months.
|
Association of baseline and perioperative characteristics (e.g. age, BMI, parity, baseline activity level, operative data, complications) with time to return to the pre-operative activity level . |
From surgery to 6 months.
|
|
Quality of early recovery (QoR-15)
Lasso di tempo: Postoperative day 1.
|
QoR-15 total score, 0-150 (higher = better recovery). |
Postoperative day 1.
|
|
Satisfaction with treatment (ICIQ-S)
Lasso di tempo: 6th week, 6th month.
|
ICIQ-S score; exploratory (working Polish translation). |
6th week, 6th month.
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Aleksandra K. Piątek, MD, PhD, Department of Minimally Invasive Gynaecology with Pelvic Floor Disorders Centre, Public Healthcare Centre of the Ministry of Interior and Administration
- Cattedra di studio: Gabriela Kołodyńska, PhD, Department of Physiotherapy Basics and Occupational Therapy, Wroclaw University of Health and Sport Sciences (AWF Wrocław)
Pubblicazioni e link utili
Pubblicazioni generali
- Urinary Incontinence Treatment Network (UITN). The Trial of Mid-Urethral Slings (TOMUS): Design and Methodology. J Appl Res. 2008;8(1):AlboVol8No1.
- Mueller MG, Lewicky-Gaupp C, Collins SA, Abernethy MG, Alverdy A, Kenton K. Activity Restriction Recommendations and Outcomes After Reconstructive Pelvic Surgery: A Randomized Controlled Trial. Obstet Gynecol. 2017 Apr;129(4):608-614. doi: 10.1097/AOG.0000000000001924.
- Lai E, McDonald K, Chopra V, Robinson L, Alvarez A, O'Shaughnessy D, Pillalamarri N, Polland A, Shalom D, Winkler H. Postoperative Activity Restrictions After Slings: A Randomized Controlled Trial. Urogynecology (Phila). 2025 Jun 1;31(6):619-626. doi: 10.1097/SPV.0000000000001515. Epub 2024 May 6.
- Alvarez P, Demirkiran C, Rickey L, Lundsberg L, Harmanli O. Activity Restrictions After Midurethral Sling: A Randomized Controlled Trial. Urogynecology (Phila). 2026 Jan 1;32(1):58-64. doi: 10.1097/SPV.0000000000001679.
- Wang R, Sappenfield EC. Return to work and normal activities after mid-urethral sling: secondary analysis of the Trial of Mid-Urethral Slings. Int Urogynecol J. 2023 Oct;34(10):2473-2477. doi: 10.1007/s00192-023-05567-5. Epub 2023 May 18.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Dolore
- Manifestazioni neurologiche
- Complicanze postoperatorie
- Processi patologici
- Malattie urogenitali maschili
- Condizioni patologiche, anatomiche
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Attributi della malattia
- Disturbi della minzione
- Sintomi del tratto urinario inferiore
- Manifestazioni urologiche
- Incontinenza urinaria
- Prolasso
- Condizioni patologiche, segni e sintomi
- Comportamento
- Segni e sintomi
- Dolore, Postoperatorio
- Incontinenza urinaria, Stress
- Prolasso degli organi pelvici
- Convalescenza
- Attività motoria
- Qualità, accesso e valutazione dell'assistenza sanitaria
- Tecniche investigative
- Metodi epidemiologici
- Terapie
- Raccolta dei dati
- Meccanismi di valutazione dell'assistenza sanitaria
- Qualità dell'assistenza sanitaria
- Sanità pubblica
- Ambiente e salute pubblica
- Controllo del comportamento
- Immobilizzazione
- Sondaggi e questionari
- Moderazione, fisico
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- RETURN-UROGYN-01
- Bioethics Committee Consent (Altro identificatore: Lower Silesian Medical Chamber)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Results will be published in aggregate form only. Participant consent and the data-protection basis (GDPR) do not cover sharing of individual-level data.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .